Palifermin for patients with haematological malignancies: Shifting nursing practice from symptom relief to prevention of oral mucositis

European Journal of Oncology Nursing

Volumn 11, Issue SUPPL. 1, 2007, Pages

  Fliedner, Monica ^a   Baguet, Brigitte ^b   Blankart, Joachim ^c   Davies, Michelle ^d   Henriques, Elisabete ^e   Leather, Angela ^f   Mazur, Ewa ^g   Mihály, Katalin ^h   Peeters, Liesbet ⁱ   Radványiné, Agnes ^g   Sedlackova, Blanka ⁱ  

^a UNIVERSITY OF BERN   (Switzerland)

^b PERCY MILITARY HOSPITAL   (France)

^c DEPARTMENT OF CARDIOLOGY   (Germany)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^f MEDICAL UNIVERSITY OF SILESIA   (Poland)

^g NATIONAL MEDICAL CENTER   (Hungary)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Haematological neoplasms; Haematopoietic stem cell transplantation; Oral mucositis; Palifermin

Indexed keywords

KERATINOCYTE GROWTH FACTOR;

ARTICLE; BLOOD DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; METHODOLOGY; MUCOSA INFLAMMATION; NURSING; ONCOLOGY NURSING; TREATMENT OUTCOME;

FIBROBLAST GROWTH FACTOR 7; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MUCOSITIS; ONCOLOGIC NURSING; TREATMENT OUTCOME;

EID: 34249323036     PISSN: 14623889     EISSN: 15322122     Source Type: Journal    
DOI: 10.1016/S1462-3889(07)70004-2     Document Type: Article

References (31)

1. Amgen, Inc. Kepivance (palifermin) Summary of Product Characteristics (2005), Amgen Europe B.V., Breda, The Netherlands
2. Beaven A.W., and Shea T.C. Palifermin: a keratinocyte growth factor that reduces oral mucositis after stem cell transplant for haematological malignancies. Expert Opinions in Pharmacotherapy 7 (2006) 2287-2299
3. Bellm L.A., Epstein J.B., Rose-Ped A., Martin P., and Fuchs H.J. Patient reports of complications of bone marrow transplantation. Supportive Care in Cancer 8 (2000) 33-39
4. Blijlevens, N.A., McCann, S., Bacon, P., Cinnéide, R., Quinn, B., Roosaar, A., et al., on behalf of the EBMT Mucositis Advisory Group, 2006. Prospective Oral Mucositis Audit (POMA): occurrence and consequences of severe oral mucositis in high dose melphalan and BEAM conditioning. Poster presented at: Annual meeting of the American Society of Hematology; December 9-12, 2006; Orlando, Florida.
5. Blijlevens N., and Sonis S. Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapyand radiotherapy-induced mucositis. Annals of Oncology (2006) [Epub ahead of print].
6. Brosa M., and Arocho R. Cost-effectiveness of the prevention of oral mucositis (OM) with Kepivance® (palifermin) in patients undergoing myeloablative therapy with autologous stem cell transplantation (ASCT) in Spain. Value in Health 9 (2006) A282
7. Coda B.A., O'Sullivan B., Donaldson G., Bohl S., Chapman C.R., and Shen D.D. Comparative efficacy of patient-controlled administration of morphine, hydromorphone, or sufentanil for the treatment of oral mucositis pain following bone marrow transplantation. Pain 72 (1997) 333-346
8. Donnelly J.P., Blijlevens N.M., and Verhagen C.A. Can anything be done about oral mucositis? [editorial]. Annals of Oncology 14 (2003) 505-507
9. Fanning S.R., Rybicki L., Kalaycio M., Andresen S., Kuczkowski E., Pohlman B., et al. Severe mucositis is associated with reduced survival after autologous stem cell transplantation for lymphoid malignancies. British Journal of Haematology 135 (2006) 374-381
10. Finch P.W., and Rubin J.S. Keratinocyte growth factor expression and activity in cancer: implications for use in patients with solid tumors. Journal of the National Cancer Institute 98 (2006) 812-824
11. Harousseau, J.L., Pico, J., Boogaerts, M.A., Bergmann, O.J., Martinez, C., Chen, M., et al., 2005. Oral mucositis is associated with increased resource utilization in patients with haematological malignancies undergoing high-dose therapy followed by autologous peripheral blood progenitor cell transplantation. Poster presented at: Annual meeting of the European Group for Blood and Marrow Transplantation; March 20-23, 2005; Prague, Czech Republic.
12. Jones J.A., Avritscher E.B., Cooksley C.D., Michelet M., Bekele B.N., and Elting L.S. Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Supportive Care in Cancer 14 (2006) 505-515
13. McDonnell A.M., and Lenz K.L. Palifermin: role in the prevention of chemotherapyand radiation-induced mucositis. Annals of Pharmacotherapy 41 (2007) 86-94
14. McGuire D.B., Altomonte V., Peterson D.E., Wingard J.R., Jones R.J., and Grochow L.B. Patterns of mucositis and pain in patients receiving preparative chemotherapy and bone marrow transplantation. Oncology Nursing Forum 20 (1993) 1493-1502
15. McQuay H., Moore A., and Justins D. Treating acute pain in hospital. BMJ 314 (1997) 1531-1535
16. Meropol N.J., Somer R.A., Gutheil J., Pelley R.J., Modiano M.R., Rowinsky E.K., et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. Journal of Clinical Oncology 21 (2003) 1452-1458
17. Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology, June 2005. Summary of evidence-based clinical practice guidelines for care of patients with oral and gastrointestinal mucositis (2005 update). Available online at: http://www.mascc.org/media/Resource_centers/Guidelines_mucositis.doc Accessed October 24, 2006.
18. Rose-Ped A.M., Bellm L.A., Epstein J.B., Trotti A., Gwede C., and Fuchs H.J. Complications of radiation therapy for head and neck cancers: the patient's perspective. Cancer Nursing 25 (2002) 461-467 quiz 468-469.
19. Rosen L.S., Abdi E., Davis I.D., Gutheil J., Schnell F.M., Zalcberg J., et al. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. Journal of Clinical Oncology 24 (2006) 5194-5200
20. Rubenstein E.B., Peterson D.E., Schubert M., Keefe D., McGuire D., Epstein J., et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100 (2004) 2026-2046
21. Siddiqui M.A., and Wellington K. Palifermin: in myelotoxic therapy-induced oral mucositis. Drugs 65 (2005) 2139-2146
22. Sonis S.T. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncology 34 (1998) 39-43
23. Sonis S.T., Oster G., Fuchs H., Bellm L., Bradford W.Z., Edelsberg J., et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. Journal of Clinical Oncology 19 (2001) 2201-2205
24. Sonis S.T. The pathobiology of mucositis. National Reviews. Cancer 4 (2004) 277-284
25. Sonis S.T., Elting L.S., Keefe D., Peterson D.E., Schubert M., Hauer-Jensen M., et al. Perspectives on cancer therapyinduced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100 (2004) 1995-2025
26. Spielberger R., Stiff P., Bensinger W., Gentile T., Weisdorf D., Kewalramani T., et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. New England Journal of Medicine 351 (2004) 2590-2598
27. Stiff P.J., Emmanouilides C., Bensinger W.I., Gentile T., Blazar B., Shea T.C., et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. Journal of Clinical Oncology 24 (2006) 5186-5193
28. Stokman M.A., Spijkervet F.K., Boezen H.M., Schouten J.P., Roodenburg J.L., and de Vries E.G. Preventive intervention possibilities in radiotherapyand chemotherapy-induced oral mucositis: results of meta-analyses. Journal of Dental Research 85 (2006) 690-700
29. Stone R., Fliedner M.C., and Smiet A.C. Management of oral mucositis in patients with cancer. European Journal of Oncology Nursing 9 Suppl 1 (2005) S24-S32
30. Woo S.B., Sonis S.T., Monopoli M.M., and Sonis A.L. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer 72 (1993) 1612-1617
31. Worthington H.V., Clarkson J.E., and Eden O.B. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database of Systematic Reviews Issue 2 (2006) CD000978.